World Journal of Nuclear Medicine最新文献

{"title":"Beyond the Fixed Dose in Theranostics: Pragmatic Dosimetry as the Missing Link in Optimizing Precision Nuclear Oncology.","authors":"Akram Al-Ibraheem, Kalevi Kairemo","doi":"10.1055/s-0046-1827826","DOIUrl":"10.1055/s-0046-1827826","url":null,"abstract":"","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"183-185"},"PeriodicalIF":1.0,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients Diagnosed with Lung Cancer by Bronchoscopy in Relation to Disease Stage and PET/CT SUVmax.","authors":"İlknur Kaya, Nuray Kurt, Ümran Erbay, Şebnem E Parspur, Feride Marım, Mehmet Doğan, Şerife Kaya","doi":"10.1055/s-0046-1827247","DOIUrl":"10.1055/s-0046-1827247","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic inflammation in lung cancer is closely associated with tumor progression and prognosis. Hematological parameters such as the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are readily available, low-cost biomarkers. This study aimed to evaluate the associations of SII, NLR, and PLR with disease stage and the maximum standardized uptake value (SUVmax) measured by ¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography ( ¹⁸ F-FDG PET/CT) in patients with lung cancer diagnosed by bronchoscopy.</p><p><strong>Materials and methods: </strong>This retrospective study included 184 of 357 patients who underwent fiberoptic bronchoscopy at the Department of Respiratory Medicine, Kütahya Health Sciences University, between January 2023 and March 2025 and had complete staging data. Demographic characteristics, histopathological diagnoses, ¹⁸ F-FDG PET/CT SUVmax values, and SII, NLR, and PLR values calculated from complete blood count parameters were recorded.</p><p><strong>Results: </strong>A total of 184 patients were included; 172 (93.5%) were male and 12 (6.5%) were female, and the mean age was 67.9 ± 8.4 years. The most common histopathological diagnosis was non-small cell lung cancer (NSCLC), accounting for 84.8% of cases. No significant associations were found between SII, NLR, or PLR and disease stage or SUVmax. NLR showed a statistically significant but very weak positive correlation with stage IV NSCLC ( <i>r</i>  = 0.198, <i>p</i>  = 0.013), indicating limited explanatory value.</p><p><strong>Conclusion: </strong>The inflammatory indices were not significantly associated with disease stage or ¹⁸ F-FDG PET/CT SUVmax. Although NLR showed a statistically significant positive correlation with stage IV NSCLC, the effect size was very small and should not be interpreted as evidence of meaningful staging utility. Larger prospective studies are needed to determine whether readily available hematological indices such as SII, NLR, and PLR provide complementary value in prognostic or multimarker models in lung cancer.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"250-254"},"PeriodicalIF":1.0,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining Soft Tissue Sarcoma Imaging: The Expanding Role of Positron Emission Tomography/Computed Tomography: A Review.","authors":"Ammad S Al Tamimi, Hamad S Al Busaidi, Mohammed A Al Mamari, Saif Z Al Salmi, Hussain I Al Bulushi, Mohammed K Al Balushi, Salim M Al Abri, Saleh S Al Abri, Qsee H Al Omairi","doi":"10.1055/s-0046-1825754","DOIUrl":"10.1055/s-0046-1825754","url":null,"abstract":"<p><strong>Background: </strong>Soft tissue sarcomas (STSs) are a heterogeneous group of mesenchymal malignancies with diverse biological behavior, posing significant challenges in tumor grading, prognostic stratification, and early treatment response assessment. While magnetic resonance imaging (MRI) remains the standard modality for local tumor evaluation, its ability to characterize tumor biology and predict clinical outcomes is limited. Advanced imaging, particularly positron emission tomography/computed tomography (PET/CT), plays a critical role in improving disease characterization and supporting personalized patient management.</p><p><strong>Methods: </strong>This narrative review summarizes the role of PET/CT in STS, focusing on established and emerging radiotracers, quantitative PET metrics, and multiparametric imaging approaches, along with their clinical applications.</p><p><strong>Results: </strong>¹⁸ F-fluorodeoxyglucose (FDG) PET/CT remains the cornerstone of functional imaging in STS, with uptake correlating with tumor grade, aggressiveness, and prognosis. Quantitative parameters such as standardized uptake values, metabolic tumor volume, and total lesion glycolysis provide additional prognostic and predictive information. Non-FDG tracers targeting proliferation, amino acid transport, perfusion, and hypoxia offer complementary insights into tumor biology. Multiparametric PET imaging improves assessment of intratumoral heterogeneity and supports biopsy guidance, radiotherapy planning, and early treatment response evaluation. Emerging approaches, including PET/MRI, radiomics, and artificial intelligence, show promise for improving tumor characterization and predictive modeling; however, these techniques remain largely investigational and require further validation before routine clinical implementation.</p><p><strong>Conclusion: </strong>PET/CT is a key modality in STS, enabling comprehensive assessment of tumor biology and supporting personalized management. Integration of quantitative metrics, novel radiotracers, and advanced analytical techniques is expected to improve diagnostic accuracy, prognostication, and treatment planning. Further large-scale studies are required to standardize methodologies and confirm clinical impact.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"186-196"},"PeriodicalIF":1.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸ F-FDG and ⁶⁸ Ga-FAPI PET/CT Imaging in a Patient with High-Grade Meningioma: A Case Report.","authors":"Arif Satria Putra Pratama, Hendra Budiawan, Trias Nugrahadi, Achmad Hussein Sundawa Kartamihardja","doi":"10.1055/s-0046-1825774","DOIUrl":"10.1055/s-0046-1825774","url":null,"abstract":"<p><p>High-grade meningiomas exhibit aggressive biological behavior and may benefit from functional imaging for further characterization. We report a 50-year-old female presenting with a 1-year history of intermittent right-sided headache and recurrent seizures. Contrast-enhanced magnetic resonance imaging demonstrated a well-defined extra-axial mass arising from the right sphenoid wing dura mater, accompanied by hyperostosis, dural tail sign, and vasogenic edema. ¹⁸ F-FDG and ⁶⁸ Ga-FAPI PET/CT ( ⁶⁸ Ga-fibroblast activation protein inhibitor positron emission tomography/computed tomography) were performed 1 week apart. FDG PET/CT demonstrated a tumor SUVmax of 7.08, comparable to the contralateral substantia nigra (SUVmax 7.27), resulting in limited lesion-to-background contrast (T/N ratio 0.97). In contrast, FAPI PET/CT showed tumor SUVmax of 3.02, with the aorta used as the background reference (SUVmean 1.76), yielding a tumor-to-background ratio of 1.71 and improved visual delineation due to minimal physiological brain uptake. Histopathology confirmed atypical meningioma (World Health Organization grade II). Although FAPI demonstrated higher tumor-to-background contrast than FDG, uptake remained relatively mild, suggesting predominant stromal mesenchymal involvement. Further comparative studies with established modalities such as somatostatin receptor PET are warranted.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"258-261"},"PeriodicalIF":1.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Intraindividual Comparison of Ga-68 PSMA and F-18 FDG Dual-Tracer PET/CT Imaging in Evaluation of High-Grade Prostate Cancer.","authors":"Harini Koorma, Mohan Roop Jayanthi, Suneetha Batchu, Anuradha Sekaran, Rajesh Kumar Reddy, Mallikarjuna Chiruvella","doi":"10.1055/s-0046-1825755","DOIUrl":"10.1055/s-0046-1825755","url":null,"abstract":"<p><strong>Introduction: </strong>High-grade prostate cancer (International Society of Urological Pathology [ISUP] grade groups 4 and 5) is often aggressive and associated with early metastatic spread. Gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is widely adopted for prostate cancer imaging due to its high sensitivity, while F-18 fluorodeoxyglucose (FDG) PET/CT may provide complementary metabolic information. This study investigates and compares the diagnostic performance of these two modalities and evaluates the incremental value of dual-tracer PET/CT imaging.</p><p><strong>Methods: </strong>This prospective observational study included 51 patients with biopsy-proven, high-grade prostate adenocarcinoma (ISUP grade groups 4 and 5) undergoing both Ga-68 PSMA and F-18 FDG PET/CT within 1 week. Detection rates for primary tumors, nodal, and distant metastases were analyzed. Maximum standardized uptake values (SUVmax), lesion-to-aorta and lesion-to-muscle ratios, and serum prostate-specific antigen (PSA) levels were correlated.</p><p><strong>Results: </strong>Ga-68 PSMA PET/CT demonstrated superior detection rate for primary tumor detection (90.2%) compared to F-18 FDG PET/CT (66.7%, <i>p</i>  = 0.004). For pelvic lymph nodes, detection rates were numerically higher with PSMA PET/CT (76.2% vs. 59.5% for FDG PET/CT), although this difference did not reach statistical significance; for extrapelvic lymph nodes, 95.2% (PSMA) versus 52.4% (FDG, <i>p</i>  = 0.02); and for bone lesions, 100% (PSMA) versus 77.8% (FDG, <i>p</i>  = 0.009). In ISUP grade 4, primary detection was 94.4% (PSMA) versus 50% (FDG, <i>p</i>  = 0.003); in grade 5, 87.9% (PSMA) versus 75.8% (FDG). Dual-tracer imaging improved overall detection of primary tumors and pelvic lymph nodes to 100 and 90.4%, respectively. A mild correlation was observed between PSA levels and PSMA SUVmax ( <i>r</i>  = 0.297, <i>p</i>  = 0.034). Strong positive correlations were found between SUVmax and both lesion-to-aorta and lesion-to-muscle ratios for both tracers. Interreader agreement was excellent for PSMA ( <i>κ</i>  = 1.00) and high for FDG ( <i>κ</i>  = 0.95).</p><p><strong>Conclusion: </strong>Ga-68 PSMA PET/CT demonstrated high detection rates for detecting primary and metastatic lesions in high-grade prostate cancer. F-18 FDG PET/CT offers complementary metabolic information, particularly valuable in ISUP grade 5 and dedifferentiated tumors. Dual-tracer PET/CT enhances diagnostic accuracy and may facilitate personalized treatment strategies in aggressive prostate cancer.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"232-241"},"PeriodicalIF":1.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real World Outcomes of Prescribed Ablative Dose Yttrium-90 Resin Selective Internal Radiation Therapy of Hepatocellular Carcinoma.","authors":"Si Xuan Koo, You Kai Poh, Nathaniel Sheng Hua Too, Wei Ming Chua, Desmond Shi Wei Lim, Charles Xian Yang Goh, Winnie Wing Chuen Lam, Kelvin Siu Hoong Loke, Aaron Kian Ti Tong","doi":"10.1055/s-0046-1825760","DOIUrl":"10.1055/s-0046-1825760","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective single-center study sought to evaluate the efficacy and safety of predictive tumor-absorbed ablative doses of Yttrium-90 resin microsphere selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>We conducted a retrospective single-center study of patients with HCC treated at a tertiary referral center, who underwent Y-90 resin SIRT with ablative intent (defined as predictive tumor absorbed dose (TAD) of at least 190 Gy via planning single-photon emission computed tomography-CT dosimetry) between January 2016 and December 2023, evaluating radiological response and survival outcomes.</p><p><strong>Results: </strong>Among 68 patients, median TAD was 262.24 Gy (interquartile range 209.13 Gy-336.26 Gy). Median follow-up was 1,231 days (approximately 40.4 months). At 6 and 12 months post-treatment, objective response (OR) and disease control rates (DCR) in the target tumors were 87.5% and 96.9%, and 73.6% and 86.8%, respectively, assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) on imaging. Median target tumor time to progression (TTP) was not reached (95% CI: 785 days - not reached); portal venous invasion was an independent predictor for shorter TTP (HR 7.34, 95% CI 1.57-34.4, <i>p</i>  = 0.011). Median progression-free survival (PFS) was 453.0 days (95% CI, 287-577). Barcelona Clinic Liver Cancer stages B/C (HR 2.87, 95% CI 1.49-5.53, <i>p</i>  = 0.0016) and the absence of subsequent curative treatment (HR 2.13, 95% CI 1.10-4.12, <i>p</i>  = 0.026) predicted for poorer PFS. Median overall survival (OS) was 1,412 days (95% CI 596-NR). Absence of subsequent curative treatment predicted for poorer OS (HR 5.23, 95% CI 1.66-16.48, <i>p</i>  = 0.005). Median OS for the 190 to 300 Gy group was 699 days (95% CI 531-2,244 days), and 1,446 days (95% CI 796 days - NR) for the TAD> 300 Gy group, though observed differences in OS between the groups were not statistically significant. Two patients had possible radiation-induced liver disease, two had post-embolization syndrome, and two had radiation-induced peptic ulcer disease. These six patients were primarily responsible for the grade 2 and 3 adverse events recorded.</p><p><strong>Conclusion: </strong>Y-90 resin SIRT with predictive TAD of at least 190 Gy in HCC can achieve favorable 1-year target tumor disease control and a median OS of 46.4 months. Absence of subsequent curative treatment independently predicted inferior progression-free and overall survival. Among plausible reasons for the absence of a clear dose-response relationship, TAD substantially higher than 190 Gy may be required for consistent ablative efficacy.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"197-207"},"PeriodicalIF":1.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of Administered Activity for ⁶⁴ Cu-SAR-bisPSMA PET Imaging in Primary Prostate Cancer: Results from a Phase I Retrospective Study (PROPELLER Sub-study).","authors":"Eva Lengyelova, Manisha Patel, Glynn Morrish, Erik Mittra, Alessandra Malaroda, Othon Gervasio, Thomas Armor","doi":"10.1055/s-0046-1824335","DOIUrl":"10.1055/s-0046-1824335","url":null,"abstract":"<p><strong>Background: </strong>⁶⁸ Ga- and ¹⁸ F-labeled prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) agents have advanced prostate cancer (PC) imaging. ⁶⁴ Cu-SAR-bisPSMA may offer several advantages for imaging of PC over standard-of-care PSMA PET agents due to its sarcophagine chelator, bivalent structure and longer half-life of ⁶⁴ Cu (12.7h vs. <2h for ⁶⁸ Ga and ¹⁸ F), which may lead to detection of additional and smaller lesions. This study determined the administered activity (AA) of ⁶⁴ Cu-SAR-bisPSMA required to achieve diagnostic-quality imaging for clinical use.</p><p><strong>Methods: </strong>The PROPELLER trial (CLP03; NCT04839367) enrolled 30 men with untreated, histopathology-confirmed, primary PC with intermediate- to high-risk features. Participants received an intravenous injection of ⁶⁴ Cu-SAR-bisPSMA at 100, 150, or 200 MBq, followed by whole-body PET/computed tomography 2 to 4 hours post-injection. Images were anonymized, randomized, and reviewed by two blinded central readers using the three-point Image Utility Classification Score. For intra-individual comparisons, a subset of images acquired at 200 MBq were digitally reconstructed to simulate 100 and 150 MBq acquisitions on the same scanner; these were randomized and then evaluated by a blinded reader. They were ranked from best image to worst image and scored with a 4-item, 5-point Likert Image Quality Score (maximum 20 points). Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were also measured.</p><p><strong>Results: </strong>Mean Image Utility Classification Score was the highest in the 200 MBq ⁶⁴ Cu-SAR-bisPSMA cohort compared with the 100 and 150 MBq cohorts (1.44, 1.17, and 0.92, respectively). For the intra-individual comparisons, images corresponding to 200 MBq were ranked as having the best image quality with a statistically significant difference in image quality ranking between AAs ( <i>p</i>  = 0.0025). The mean Image Quality Score was highest at 200 MBq of ⁶⁴ Cu-SAR-bisPSMA (16.0 ± standard deviation 1.10) versus 150 MBq (12.2 ± 1.17) and 100 MBq (10.3 ± 1.63). Quantitatively, 200 MBq of ⁶⁴ Cu-SAR-bisPSMA had the greatest SNR in both the liver and prostate and the highest CNR for liver relative to the gluteus muscle.</p><p><strong>Conclusions: </strong>An AA of 200 MBq was identified as the optimal AA for ⁶⁴ Cu-SAR-bisPSMA PET, yielding improved image quality across both qualitative and quantitative metrics compared with 150 and 100 MBq. These findings support the selection of 200 MBq for clinical studies evaluating ⁶⁴ Cu-SAR-bisPSMA as an imaging agent for PC. NCT04839367, Registered 2021-04-07.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 2","pages":"107-114"},"PeriodicalIF":1.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of F-18 FDG PET-Based Metabolic Parameters in the Differential Diagnosis of Esophageal Squamous Cell Carcinoma and Adenocarcinoma.","authors":"Priyank Rajput, Deepanksha Datta, Rajesh Kumar","doi":"10.1055/s-0046-1824603","DOIUrl":"10.1055/s-0046-1824603","url":null,"abstract":"<p><strong>Purpose: </strong>Intratumoral heterogeneity is a primary driver of treatment resistance in many malignancies, including esophageal cancer. While Fluorine-18 Fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) is a standard tool for staging and response assessment in the esophageal malignancy, the qualitative visual assessment of primary tumor and metastases is limited by interobserver variability. The purpose of this study is to determine if the non-invasive imaging biomarkers on F-18 FDG PET can reliably distinguish the two primary histological subtypes of esophageal malignancy namely squamous cell carcinoma (SCC) and adenocarcinoma (AC).</p><p><strong>Methods: </strong>This is a retrospective study approved by the institutional ethical committee, and conducted in histopathologically proven cases of esophageal malignancy of either squamous cell or AC subtypes, who underwent baseline staging F-18 FDG PET/CT as per the standard guidelines. The metabolic parameters namely tumoral maximum standardized uptake value (SUVmax), total lesional glycolysis (TLG), metabolic tumor volume (MTV) and metabolic ratio of tumor to liver (standardized uptake ratio [SUR]) were calculated and compared between the two histological subtypes using Mann - Whitney U test. A <i>p</i> -value of less than 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Out of 59 patients (M:F = 33:26) included in the study, 40 had squamous cell subtype and 19 had AC. Median age was 57 years (range: 30-83), and the median SUVmax, SUR, MTV, and TLG of AC group was 10.89 g/mL, 3.86, 9.98 mL, and 55.8 g/mL, while that of squamous group was 13.88 g/mL, 5.6, 13.52 mL, and 108.4 g/mL, respectively. There was significant difference noted in the tumoral SUVmax ( <i>p</i>  = 0 <i>.043)</i> , SUR ( <i>p</i>  = 0 <i>.019</i> ), and TLG ( <i>p</i>  = 0 <i>.032</i> ) between the two groups, with higher metabolic values observed in the squamous group. MTV ( <i>p</i>  = 0 <i>.224</i> ) between the two groups was insignificant.</p><p><strong>Conclusion: </strong>This study demonstrates that quantitative parameters on F-18 FDG PET are effective non-invasive biomarkers for differentiating the histological subtypes of esophageal malignancy. The squamous cell subtype exhibits significantly higher metabolism and total lesion glycolysis than AC.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 2","pages":"115-120"},"PeriodicalIF":1.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13327742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer.","authors":"Cihan Şin, Burcu Esen Akkaş, Özge Vural Topuz, Özgür Omak, Enes M Kaya, Harun Özdemir, Begüm Çalım Gürbüz, Halil L Canat, Abdulmuttalip Şimşek, Meryem Kaya","doi":"10.1055/s-0046-1824462","DOIUrl":"10.1055/s-0046-1824462","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the diagnostic performance of diuretic-enhanced dual-phase F-18 FDG PET/CT in detecting muscle invasion in bladder cancer (BC) and to evaluate the predictive role of metabolic and volumetric PET parameters.</p><p><strong>Methods: </strong>A total of 105 patients (85 males, 20 females; mean age: 67.8 years) with suspected BC underwent F-18 FDG PET/CT for initial staging. Routine and delayed pelvic imaging was performed after intravenous furosemide. Metabolic and volumetric parameters, including SUV _max , SUV _mean , metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured and correlated with histopathological findings. Statistical analyses consisted of Mann-Whitney U, Kruskal-Wallis, and Receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>Distant metastases were detected in 30 patients (28.5%), which directly influenced treatment decisions. In the TUR-B cohort ( <i>n</i>  = 75), F-18 FDG PET/CT demonstrated a sensitivity of 78.0%, specificity of 62.5%, positive predictive value of 88.5%, negative predictive value of 43.5%, and an overall accuracy of 74.7% in differentiating malignant from benign bladder lesions. Among the 59 patients with confirmed malignancy, volumetric parameters correlated with pathological T-stage. Patients with T2 tumors had significantly higher SUV _max , SUV _mean , MTV, and TLG values compared with <T2 tumors ( <i>p</i>  < 0.001). ROC analysis confirmed the discriminative value of MTV (AUC: 0.814) and TLG (AUC: 0.830), with reliable cutoff values identified.</p><p><strong>Conclusion: </strong>Diuretic-enhanced dual-phase F-18 FDG PET/CT provides clinically valuable information for the assessment of detrusor muscle invasion and the differentiation of bladder lesions. Quantitative volumetric and metabolic parameters may serve as surrogate biomarkers, supporting preoperative staging and contributing to more precise, personalized treatment strategies for patients with BC.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"242-249"},"PeriodicalIF":1.0,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸ F-FDG PET/CT in Cardiac Sarcoidosis: Pioneering Evidence from the Arab Middle East.","authors":"Joe Rizkallah, Omar El Sardouk, Safaa Al Zakleet, Nina Saliba, Marwan Refaat, Habib Dakik, Diana Paez, Thomas N B Pascual, Enrique Estrada-Lobato, Francesco Giammarile, Alain S Abi-Ghanem, Mohamad Haidar","doi":"10.1055/s-0046-1824539","DOIUrl":"10.1055/s-0046-1824539","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiac sarcoidosis can lead to arrhythmias, heart failure, and sudden cardiac death. Positron emission tomography/computed tomography (PET/CT) is crucial for diagnosis and monitoring, yet data from the Middle East and North Africa (MENA) region remain scarce. This study evaluated the role of PET/CT in diagnosing and managing cardiac sarcoidosis at a tertiary referral center in the Middle East.</p><p><strong>Materials and methods: </strong>This retrospective study included 19 patients with biopsy-proven sarcoidosis who underwent fluorine-18 fluorodeoxyglucose (FDG) PET/CT for suspected cardiac involvement at a tertiary referral medical center in Lebanon between 2014 and 2024. Complementary imaging with echocardiography, cardiac magnetic resonance imaging, and electrocardiography was also analyzed alongside treatment approaches and follow-up outcomes.</p><p><strong>Results: </strong>FDG PET/CT identified cardiac involvement in 12 patients, with diffuse or focal FDG uptake patterns correlating with symptom severity and electrocardiographic abnormalities. These patients exhibited higher rates of arrhythmias, conduction abnormalities, and reduced global longitudinal strain and E/A ratio on echocardiography. Cardiac magnetic resonance imaging demonstrated late gadolinium enhancement in most cases with FDG PET/CT-confirmed cardiac sarcoidosis, supporting the presence of myocardial inflammation. Treatment included corticosteroids, immunosuppressive agents, and device implantation in selected cases. Follow-up FDG PET/CT showed significant reductions in FDG uptake, indicating therapeutic response.</p><p><strong>Conclusion: </strong>This study underscores the clinical utility of FDG PET/CT in diagnosing and managing cardiac sarcoidosis, particularly in resource-limited settings like the MENA region. FDG PET/CT enabled early detection, guided treatment decisions, and facilitated monitoring of therapeutic response. These findings highlight the need for broader access to FDG PET/CT imaging in the region to optimize patient outcomes.</p>","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"25 3","pages":"219-231"},"PeriodicalIF":1.0,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}